Our mission is to revolutionise cancer diagnosis and therapeutics with the development and distribution of tools and technologies powered by epigenetics. Our dedication to scientific excellence begins with our co-founder, Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, which underpins the market-leading Illumina® sequencing technology. Our team of leading laboratory professionals and bioinformaticians are dedicated to bringing our science into clinical practice.

Our Timeline

Founded in 2012 by Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing which underpins the market-leading Illumina® sequencing technology, and Dr Bobby Yerramilli-Rao, Cambridge Epigenetix is pioneering the epigenetics revolution.

  1. Seminal 5hmC publications released

    Professor Anjana Rao’s team at Harvard Medical School and Dr Nathaniel Heintz’s group at Rockefeller University independently publish on a new epigenetic DNA modification - 5-hydroxymethylcytosine (5hmC).

  2. oxBS technique invented

    The technique of oxBS is invented by Professor Sir Shankar Balasubramanian’s group at the University of Cambridge, allowing, for the first time, single-base resolution analysis of 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC).

  3. Cambridge Epigenetix founded

    Cambridge Epigenetix founded to commercialise oxBS, providing access to the wider epigenetics research community.

  4. TrueMethyl oxBS kits launched

    TrueMethyl oxBS kits launched providing reproducible and accurate analysis of 5hmC and 5mC.

  5. £5.5M Series A funding round

    Cambridge Epigenetics raises $5.5M in Series A funding to further develop and commercialise tools for epigenetic analysis.

  6. $21M Series B funding round

    Cambridge Epigenetics raises $21M in Series B funding to support further expansion of the business and investment in initial epigenetic biomarker discovery programmes utilising our proprietary platforms.

  7. New TrueMethyl Kit launched

    TrueMethyl Whole Genome kit launched to further streamline epigenetics discoveries.

  8. High-profile SAB established

    Cambridge Epigenetix establishes Scientific Advisory Board comprising experts within oncology, liquid biopsy and ageing to further drive the company’s transition towards epigenetic biomarker discovery.

  9. Fundamental methylation IP licensed

    Cambridge Epigenetix licenses fundamental DNA methylation IP from Boston Children’s Hospital providing exclusive access to best-in-class techniques and freedom to commercialise novel epigenetic assays.

  10. HMCP: A disruptive new discovery platform

    The company develops HMCP, a highly sensitive, high-throughput platform for high-resolution analysis of 5hmC, enabling cost-effective biomarker discovery.

  11. 5hmC diagnostic pilot study

    Pilot studies using HMCP allow stratification of case vs control samples for a range of cancer types from liquid biopsy (LQB) samples - allowing the development of minimally invasive epigenetic-based assays for early cancer detection.

  12. New purpose-built facilities

    Rapid growth prompts move to new purpose-built facilities allowing further expansion of biomarker discovery and validation capabilities.

  13. TrueMethyl licensed to NuGEN

    Cambridge Epigenetix licenses TrueMethyl oxBS technology to NuGen Technologies Inc, allowing the company to fully focus on epigenetic biomarker discovery and diagnostic assay development programmes.

Our Team

Gail Marcus

Executive Chair

Gareth Ridge

Senior Vice President of Operations & Site Head

Dr. Joanna Holbrook

Senior Vice President of Research

Professor Sir Shankar Balasubramanian FRS

Founder, Director & Senior Advisor on Science & Technology

Dr. Bobby Yerramilli-Rao


Tom Hulme

General Partner, GV

Alice Newcombe-Ellis

Managing Partner, Ahren Innovation Capital

Somu Subramaniam

Co-Founder and Managing Partner, New Science Ventures

Roelof F. Botha

Partner, Sequoia Capital (Observer)

Professor Wolf Reik

Head of the Epigenetics Programme, Babraham Institute

Professor Anjana Rao

Head of the Division of Signalling and Gene Expression, La Jolla Institute

Professor Mark Dawson

Group Leader of the Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre

Together, we will make disease optional, not inevitable

Join UsCareers